secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001104659-26-016410
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos Q4 record sales $143.1M (+36% YoY); reaffirms FY2026 guidance $600-620M
-------------------------------------------------------------------------------

- Q4 net sales $143.1M (record), +36% YoY; full year $507.4M, +32% YoY.
- GAAP net loss $133.7M ($2.32/sh) includes $112.9M non-cash impairment on Avedro intangible.
- Non-GAAP net loss improved to $16.4M ($0.28/sh) from $22.2M ($0.40) in Q4 2024.
- U.S. Glaucoma sales record $86.4M, +53% YoY; strong growth from iDose TR.
- Ended Q4 with $282.6M cash, no debt; 2026 revenue guidance reaffirmed at $600-620M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/0001104659-26-016410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000110465926016410/gkos-20260217x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-016410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer